登录 注册 会员服务 联系我们

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine

  • Published:2023-10-19 Issue:3 Volume:19 Page:
  • ISSN:2164-5515
  • Container-title:Human Vaccines & Immunotherapeutics
  • language:en
  • Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Yong Xiaolan1,Liu Jun2,Zeng Ying34,Nie Jing2,Cui Xuelian5,Wang Tao5,Wang Yilin5,Chen Yiyong5,Kang Wei34,Yang Zhonghua34,Liu Yan56

Affiliation:

1. Phase I Clinical Trial Center, Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan, China

2. Pulmonary and Critical Care Medicine, Chongqing Red Cross Hospital (People’s Hospital of Jiangbei District), Chongqing, China

3. Department of Medicine and Registration, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, China

4. Department of Medicine and Registration, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, China

5. Department of Medicine, Chongqing Medleader Bio-Pharm Co. Ltd, Chongqing, China

6. College of Pharmacy, Chongqing Medical University, Chongqing, China

Funder

Key Program of the Yantai Science & Technology

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3